Core Viewpoint - The article discusses the significant shift in the medical aesthetics industry, highlighting the transition from conflict to collaboration between companies like Jinjing Biological and platforms like New Oxygen, reflecting changes in market dynamics and pricing power [1][3][5]. Group 1: Industry Dynamics - In 2024, Jinjing Biological publicly criticized New Oxygen for low-price promotions of its core product, Wei Yimei, indicating a struggle to maintain pricing power [1][4]. - New Oxygen has transformed from a platform to a physical clinic model, establishing 50 stores across 16 cities, which enhances its bargaining power with upstream manufacturers [3][11]. - The monopoly of Jinjing Biological in the collagen product market has been disrupted by competitors like Juzhi Biological and Chuangjian Biological, leading to a loss of pricing authority for upstream manufacturers [3][10]. Group 2: Strategic Alliances - The formation of the "Youth Selection Alliance" by New Oxygen and 14 upstream manufacturers, including Jinjing Biological, marks a shift towards collaboration in areas like pricing and product traceability [2][5]. - Jinjing Biological's previous confrontations with platforms like Meituan have also turned into strategic partnerships, indicating a broader trend of upstream manufacturers adapting to market realities [7][10]. Group 3: Evolving Business Models - The article outlines three emerging strategies for upstream manufacturers in response to shifting market dynamics: 1. The rise of the ODM model, where companies like Xihong Biological provide products without interfering with downstream pricing [14]. 2. Maintaining product scarcity through innovation or acquisitions to capture market share during competitive gaps [15]. 3. Expanding internationally to seek new growth opportunities, as seen with companies like Aimeike and Binhai Medical [15][16]. Group 4: Market Trends - The medical aesthetics market is experiencing a significant increase in product offerings, with over 50 new medical device approvals in 2025, leading to intensified competition [11]. - The shift in pricing power from manufacturers to distribution channels reflects a broader trend of market "demystification" and value reassessment in the medical aesthetics sector [16].

Core Insights - The article highlights the launch of two significant products, the Peninsula Super Cannon and Peninsula Counterclockwise, by Peninsula Medical Group, which recently received NMPA Class III medical device registration [1][3] - These products aim to address deep support and superficial repair in aesthetic medicine, utilizing advanced technology to achieve comprehensive treatment from the fascia layer to the epidermis [1][2] - The company emphasizes its commitment to making advanced medical equipment accessible to thousands of hospitals in China, which were previously dominated by international giants [1] Product Innovations - The Peninsula Golden Microneedle introduces dynamic layered treatment technology, allowing for targeted treatment across five skin layers with a single needle insertion, addressing uneven energy distribution and enhancing patient comfort [2] - The Peninsula Counterclockwise, as the first domestic Class III radiofrequency microneedle, resolves the industry challenge of balancing efficacy and comfort through multi-dimensional technological innovations [2] - The Peninsula Super Cannon, the first globally to receive NMPA Class III certification for focused ultrasound skin treatment, boasts a 50% efficiency improvement and integrates high-resolution ultrasound imaging with treatment processes [3] Market Position and Growth - China is identified as the fastest-growing market for photonic anti-aging treatments, with ultrasound and radiofrequency microneedles accounting for over 60% of the market share [4] - Following its certification, the Peninsula Super Cannon experienced a surge in search interest, indicating strong market potential and consumer engagement [4] - The company has also secured multiple international certifications, including FDA and CE, positioning itself to compete on a global scale and potentially lead in the medical aesthetic device market [4]

Core Insights - The article highlights the launch of two new medical devices, Peninsula Super Cannon and Peninsula Counterclockwise, which have received NMPA Class III medical device registration and are now certified by FDA and CE, marking a significant step for the company in the global aesthetic medical market [1][2] Company Overview - Peninsula Medical, founded by Lei Xiaobing, aims to make advanced medical equipment affordable for thousands of hospitals in China that were previously dominated by international giants [1] - The company has expanded from Chongqing to Shanghai and finally established its base in Shenzhen, with products now sold in over 70 countries and regions, serving thousands of hospitals and aesthetic institutions [1] - The company boasts a research and development team of nearly 400 people, bridging clinical needs with engineering technology [1] Product Innovations - The Peninsula Super Cannon integrates a high-resolution intelligent ultrasound imaging system with treatment processes, introducing the SOP 3.0 precision treatment system, which allows for visual, quantifiable, and traceable treatment standards [2] - The Peninsula Counterclockwise, as the first domestic Class III radiofrequency microneedle device, addresses the industry pain point of balancing efficacy and comfort, utilizing multi-dimensional technological innovations [2] - Key features of the Peninsula Counterclockwise include layered treatment technology, mixed mode output, and a significant increase in energy delivery efficiency, which enhances patient comfort and reduces recovery time [2] Market Potential - According to third-party market research firm, Sullivan, China has become the fastest-growing market for photonic anti-aging treatments, with ultrasound and radiofrequency microneedles accounting for over 60% of the market, driving core growth in the industry [3] - The company expresses confidence in the future of Chinese aesthetic medical device enterprises and service institutions becoming global brands [3]

Core Insights - Peninsula Medical is experiencing rapid growth in user trust, with over 1 user receiving anti-aging or skin rejuvenation treatments every minute, and its core products have treated over 4 million users [1] - The company launched two new products, "Peninsula Big Ultrasound" and "Peninsula Counterclockwise," both of which received the highest medical device certification in China [1] - The market for anti-aging treatments in China is rapidly expanding, with 99.7% of consumers considering anti-aging important, creating significant demand for Peninsula's new products [2] Product Performance - The "Peninsula Big Ultrasound" has gained significant market attention since its NMPA III class certification, quickly becoming a trending product on social media [2] - The product's strong market performance is evidenced by high user satisfaction and repeat purchase rates, indicating its potential as a market leader [2][3] - Clinical trials for the "Peninsula Counterclockwise" show over 96% effectiveness in scar improvement and high user satisfaction rates [5][6] Technological Advancements - The "Peninsula Counterclockwise" is the first domestic product to receive both NMPA and FDA certifications, addressing key industry challenges by balancing effectiveness and comfort [4] - The "Peninsula Big Ultrasound" features advanced technology that improves energy efficiency by over 50% compared to previous models, enhancing treatment comfort and precision [5] Industry Impact - Peninsula Medical's commitment to social responsibility is highlighted by its participation in charity auctions, setting a new record in the beauty industry [3] - The company has established a strong research and development foundation, with over 1,000 patent applications and a dedicated team of nearly 400 researchers [7] - Through training programs, Peninsula Medical has certified over 12,000 professional physicians, contributing to the overall improvement of industry standards [8] Strategic Vision - Peninsula Medical aims to lead the high-end medical aesthetics market in China and globally, focusing on long-term growth and innovation [9] - The company emphasizes the integration of scientific research and clinical practice to enhance user experience and product effectiveness [9]

Core Viewpoint - The article highlights the launch of two significant products by the company, namely the Peninsula Super Cannon and the Peninsula Counterclockwise, which represent advancements in domestic medical aesthetic equipment and aim to lead the industry towards standardization and global competitiveness [1][3][18]. Product Launch - The Peninsula Super Cannon is the first ultrasound skin treatment device to receive a Class III medical device registration certificate from the National Medical Products Administration (NMPA) [1]. - The Peninsula Counterclockwise is the first domestic Class III radiofrequency skin treatment device to obtain both NMPA and FDA certifications [1]. Technological Advancements - Both products are the result of years of technological innovation and rigorous clinical trials, with the Super Cannon showing an efficacy rate of over 82% in improving skin laxity and a satisfaction rate exceeding 88% three months post-treatment [5]. - The Counterclockwise demonstrated a scar improvement efficacy rate of over 96% and a satisfaction rate close to 98% three months after treatment [7]. Industry Impact - The introduction of these products is seen as a step towards standardizing the medical aesthetic equipment industry in China, which has historically been dominated by international players [11][12]. - The company has been proactive in establishing clinical standards and training programs, having trained over 9,000 certified ultrasound physicians and 3,000 certified Counterclockwise physicians [9]. Market Position - The company has positioned itself among the top six global energy source medical aesthetic equipment manufacturers, with its products sold in over 70 countries and regions [18]. - The emergence of the Super Cannon and Counterclockwise signifies a shift in the domestic market from low-end competition to high-end innovation, marking China's entry into the global competitive landscape [20]. Research and Development - The company invests over 25% of its revenue annually into research and development, employing a team of nearly 400 researchers, which constitutes about 30% of its total workforce [16]. - The company has applied for over 1,000 domestic and international patents, with more than 400 granted, establishing a strong technological moat [16].

Core Insights - Peninsula Medical has launched two significant products, the Peninsula Super Cannon and the Peninsula Counterclockwise, which are set to lead the medical aesthetics equipment industry towards standardization and represent a breakthrough for domestic technology in the global market [1][4][27]. Product Launch - The Peninsula Super Cannon is the first ultrasound skin treatment device to receive a Class III medical device registration from the Chinese National Medical Products Administration (NMPA) [1][27]. - The Peninsula Counterclockwise is the first domestic Class III radiofrequency skin treatment device to achieve dual certification from both the NMPA and the U.S. FDA [1][27]. Industry Impact - The introduction of these products is seen as a move towards standardization in the medical aesthetics industry, which is increasingly influenced by the "beauty economy" and advancements in photonic technology [5][12]. - The medical aesthetics equipment market in China has significant growth potential, with the penetration of photonic medical aesthetics technology driving the development of downstream services [16][30]. Research and Development - Peninsula Medical has invested heavily in R&D, allocating over 25% of its revenue annually, and has a dedicated R&D team of nearly 400 people, constituting 30% of its total workforce [21][27]. - The company has filed over 1,000 domestic and international patents, with more than 400 granted, establishing a strong technological moat [21]. Clinical Validation - The clinical trials for the Peninsula Super Cannon involved 204 subjects, showing an efficacy rate of over 82% in improving skin laxity, with a satisfaction rate exceeding 88% three months post-treatment [7][9]. - The clinical data for the Peninsula Counterclockwise indicated a scar improvement efficacy rate of over 96% and a satisfaction rate close to 98% three months after the procedure [9]. Market Position - Peninsula Medical has positioned itself among the top six global energy source medical aesthetics equipment companies, with its products sold in over 70 countries and regions, serving more than 10,000 well-known hospitals [27]. - The launch of these products marks a shift in the domestic medical aesthetics equipment landscape, moving from low-end market competition to achieving international certifications and recognition [27][30].

Core Viewpoint - The article highlights the rapid growth of China's medical aesthetics equipment industry, showcasing the emergence of domestic brands like Peninsula Medical, which are gaining market share and technological advancements in the field [3][19]. Industry Growth - The domestic medical aesthetics equipment market is projected to exceed 32 billion yuan by 2024, with a compound annual growth rate (CAGR) of 13%-15% [3]. - The market share of domestic equipment has increased from 38% in 2020 to 42% in 2024, with energy source segments like radiofrequency and intense pulsed light reaching a 46% share [3]. Product Innovation - Peninsula Medical's two core products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, represent significant advancements in energy source medical aesthetics devices, with a focus on clinical needs and technological innovation [3][5]. - The Peninsula Ultra Cannon is the first and only ultrasound medical aesthetics device to receive NMPA Class III certification, achieving precise anti-aging treatment from the epidermis to the SMAS layer [3][5]. - The Peninsula Counterclockwise is the first domestic radiofrequency medical aesthetics device to obtain NMPA Class III certification, featuring innovative technologies for effective treatment [5][7]. Clinical Research and Efficacy - Clinical studies led by top hospitals show that the Peninsula Ultra Cannon has an effectiveness rate of over 89% in improving skin laxity, with a satisfaction rate exceeding 90% among participants [5]. - Since its launch in 2021, the Peninsula Ultra Cannon has been used in over 4 million treatments, averaging more than 3,000 treatments per day [5]. R&D and Patents - Peninsula Medical has a strong focus on R&D, with nearly 400 staff dedicated to research, accounting for 30% of total employees, and R&D investment representing 25%-27% of sales revenue [9]. - The company has filed over 1,000 domestic and international patents, with more than 70 global certifications, and has played a role in drafting industry standards [9][19]. International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of China's medical aesthetics professionals [11]. - Peninsula Medical's collaboration with Boston Aesthetics aims to bridge the gap between Chinese R&D and U.S. clinical needs, facilitating the entry of Chinese products into the global market [12][18]. Market Trends - The export value of domestic medical aesthetics equipment is expected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [19]. - The industry is transitioning from a focus on cost-effectiveness to differentiation, with domestic companies targeting specific needs of Asian skin types [14][19]. Future Outlook - The integration of artificial intelligence with medical aesthetics devices is emerging as a new trend, enabling personalized treatment parameters [19]. - The industry is poised for a comprehensive upgrade from "Made in China" to "Intelligent Manufacturing in China," driven by companies focused on R&D and clinical needs [19].

Core Insights - Peninsula Medical showcased its brand on the Nasdaq screen, highlighting its rapid growth in the Chinese medical aesthetics industry, with the domestic medical aesthetic equipment market projected to exceed 32 billion yuan by 2024, maintaining a compound annual growth rate of 13%-15% [1][11] - The company presented two NMPA Class III certified products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, in collaboration with Boston Aesthetics and numerous Chinese dermatologists and plastic surgeons [1][2] Industry Growth - The domestic medical aesthetic equipment market is expected to grow significantly, with the share of domestic equipment increasing from 38% in 2020 to 42% in 2024, particularly in energy source segments like RF and IPL, where domestic brands now hold a 46% market share [1][11] - The clinical demand drives technological innovation, with Peninsula Medical focusing on addressing industry pain points through medical-engineering collaboration [2][3] Product Innovation - The Peninsula Ultra Cannon is the first globally to receive NMPA Class III certification for ultrasound medical aesthetics, achieving over 89% effectiveness in improving skin laxity in clinical studies [2][3] - The Peninsula Counterclockwise is the first domestic RF medical aesthetic device to receive NMPA Class III certification, featuring innovative technologies for precise depth control in clinical applications [3][4] Research and Development - Peninsula Medical has a robust R&D team of nearly 400, accounting for 30% of its workforce, with R&D investment constituting 25%-27% of sales revenue, which is high for the industry [4][5] - The company has filed over 1,000 domestic and international patents and has received more than 70 global certifications, contributing to the industry's shift from imitation to independent innovation [5][11] International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of Chinese medical aesthetics professionals [6][11] - Peninsula Medical's Boston Aesthetics team is pivotal in bridging Chinese R&D with U.S. clinical needs, having successfully registered the Peninsula Counterclockwise in the U.S. [7][10] Market Trends - The international competitiveness of domestic devices is shifting from cost-effectiveness to differentiated advantages, focusing on the unique characteristics of Asian skin [8][9] - The export value of domestic medical aesthetic devices is projected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [11]

Core Insights - The first domestic radiofrequency microneedle device, known as "Haidao Reverse Time," has received the Class III medical device registration certificate in China, marking a significant regulatory milestone for the company [1][2] - This device is the first in China to obtain both NMPA and FDA certifications, aligning with regulatory trends for radiofrequency products [2] - The approval of "Haidao Reverse Time" is expected to accelerate the expansion of domestic radiofrequency products, as companies aim to meet the upgraded regulatory standards [3] Regulatory Developments - The approval of the Class III medical device certificate aligns with the regulatory direction for radiofrequency products, as outlined in the announcement by the drug administration in July 2024 [2] - Starting from April 1, 2026, radiofrequency treatment devices will need to upgrade from Class II to Class III medical device registration, prompting companies to adapt quickly [2][3] Product Features and Market Impact - "Haidao Reverse Time" integrates monopolar, bipolar, and combined modes of radiofrequency microneedling, enhancing treatment efficiency and patient comfort [2] - The device is primarily used for treating acne and offers significant time savings and reduced discomfort compared to traditional methods [2] - The regulatory upgrade is expected to filter out less capable companies, fostering a shift from quantity expansion to quality competition in the domestic radiofrequency product market [3]

Core Insights - Peninsula Medical's product ZenTite has been installed at the Wellman Center for Photomedicine in Boston, marking a significant step in the company's global strategy and showcasing the international presence of Chinese medical aesthetic brands [1][2] - The Wellman Center, affiliated with Harvard Medical School, is a leading institution in photomedicine research and clinical applications, enhancing the credibility of the installation [1] - Dr. R. Rox Anderson, a prominent figure in laser science and medicine, led the installation, highlighting the product's acceptance by influential experts in the field [1][3] Company Developments - Since obtaining FDA 510(k) registration for its Golden Microneedle in early 2023, Peninsula Medical has accelerated the deployment of its major equipment in six renowned hospitals in the U.S., including five installations of ZenTite [2] - The company has also successfully installed its ultrasound device at the Beckman Laser Institute & Medical Clinic, marking its first entry into the U.S. market with this product [2][3] Industry Position - Peninsula Medical is recognized as a leading brand in the global photomedicine and aesthetic device market, with a strong emphasis on collaboration with clinical experts to drive product development [3][4] - The company has a significant R&D workforce, with nearly 400 researchers, representing 30% of its total employees, and holds an 80% market share in the domestic ultrasound aesthetic sector [4]